Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGA4 | P13612 | 1/20 | 0.40 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.40 |
| ▸ | MKNK1 | Q9BUB5 | 5/20 | 0.36 |
| ▸ | MKNK2 | Q9HBH9 | 5/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.36 |
| ▸ | CDC7 | O00311 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 7/20 | 0.35 |
| ▸ | JAK1 | P23458 | 7/20 | 0.35 |
| ▸ | CHUK | O15111 | 1/20 | 0.35 |
| ▸ | TYK2 | P29597 | 6/20 | 0.34 |
| ▸ | JAK3 | P52333 | 1/20 | 0.33 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.33 |
| ▸ | MTOR | P42345 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3342461 | 0.86 | P2RX7 (0.43) | ITGA4ITGB7MKNK1MKNK2P2RX7 | |
| SCHEMBL3344631 | 0.84 | P2RX7 (0.40) | ITGA4ITGB7MKNK1MKNK2P2RX7 | |
| SCHEMBL3342657 | 0.83 | ITGA4 (0.38) | ITGA4ITGB7P2RX7 | |
| SCHEMBL3348215 | 0.77 | PIK3R2 (0.38) | ITGA4ITGB7MKNK1MKNK2P2RX7 | |
| SCHEMBL6526034 | 0.75 | RAB9A (0.41) | MKNK1MKNK2P2RX7CDC7JAK2 | |
| SCHEMBL3343187 | 0.73 | P2RX7 (0.47) | ITGA4ITGB7MKNK1MKNK2P2RX7 | |
| SCHEMBL9903611 | 0.73 | SIRT3 (0.39) | JAK1TYK2JAK3 | |
| SCHEMBL1226389 | 0.71 | P2RX7 (0.41) | ITGA4ITGB7P2RX7 | |
| SCHEMBL30542171 | 0.70 | ITGA4 (0.42) | ITGA4ITGB7P2RX7 | |
| SCHEMBL27754183 | 0.70 | ITGA4 (0.44) | ITGA4ITGB7P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100160384-A1 | DIHYDROPYRIDONE AMIDES AS P2X7 MODULATORS | ROCHE PALO ALTO LLC | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160384-A1 | DIHYDROPYRIDONE AMIDES AS P2X7 MODULATORS | P2RY1, P2RX6, P2RX3 | ITGA4 2788/4885ITGB7 4065/4885MKNK1 2405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.